Intratumoral Influenza Vaccine for Early Colorectal Cancer

Summary

The aim of this explorative phase II clinical trial is to establish the safety and efficacy of intratumoral influenza vaccine in patients with colorectal cancer, as an additive treatment prior to intended curative surgery.

Timeline

Start

2021-02-26

Primary completion

2021-09-22

Completion

2021-11-01

Outcome

Met primary endpoint

paper No endoscopic safety events occurred, with all patients undergoing curative surgery as scheduled PMID 37172969 ↗

paper Neoadjuvant intratumoral influenza vaccine treatment in this cohort was demonstrated to be safe and feasible PMID 37172969 ↗

Publications

• Gogenur M, Balsevicius L, Bulut M, Colak N, Justesen TF, Fiehn AK, Jensen MB, Host-Rasmussen K, Cappelen B, Gaggar S, Tajik A, Zahid JA, Bennedsen ALB, D'Ondes TDB, Raskov H, Saekmose SG, Hansen LB, Salanti A, Brix S, Gogenur I. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial. J Immunother Cancer. 2023 May;11(5):e006774. doi: 10.1136/jitc-2023-006774.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Influenza Vaccines	Vaccine	—	Other

Indications